Citigroup’s Medicus Pharma MDCX Stock Holding History

Citigroup’s Portfolio MDCX Stock Details MDCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-222	Closed	-$514	–	6589
2025 Q3	$514	Buy	+222	New	+$557	﹤0.01%	5701

Other funds holding MDCX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

ICP

Interchange Capital Partners Pittsburgh, Pennsylvania $532M AUM 26.57% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

WSFS

Wilmington Savings Fund Society Wilmington, Delaware $4.48B AUM 24.77% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MHC

May Hill Capital Cohasset, Massachusetts $398M AUM 23.9% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Citigroup's MDCX Position: Q4 2025 in Review

Citigroup sold out of Medicus Pharma (MDCX) in Q4 2025, closing a stake of 222 shares — an estimated $514 sold.

Citigroup first reported a position in MDCX in Q3 2025 and held it in 1 quarter. The position peaked at $514 in Q3 2025. 21 funds tracked by Wall St. Rank hold MDCX as of Q4 2025.

Citigroup reported no remaining Medicus Pharma position as of Q4 2025 after selling out during the quarter.
Citigroup sold 222 Medicus Pharma shares in Q4 2025, an estimated $514.
Citigroup first reported a position in Medicus Pharma in Q3 2025 and held it in 1 quarter.
Citigroup's Medicus Pharma position peaked at $514 in Q3 2025.
21 funds tracked by Wall St. Rank held Medicus Pharma as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.